Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

被引：0
|
作者：
Kensei Tobinai
Toshiki Uchida
Noriko Fukuhara
Tomoaki Nishikawa
机构：
[1] National Cancer Center Hospital,Department of Hematology
[2] Japanese Red Cross Nagoya Daini Hospital,undefined
[3] Tohoku University Hospital,undefined
[4] Janssen Pharmaceutical K.K.,undefined
来源：
International Journal of Hematology | 2019年 / 109卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：366 / 368
页数：2
相关论文
共 50 条
  • [31] A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Crombie, Jennifer L.
    Kim, Austin I.
    Bartlett, Nancy L.
    Redd, Robert A.
    Patterson, Victoria
    Carey, Celeste
    Balasubramanian, Sobana
    Odejide, Oreofe O.
    Merryman, Reid W.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Fisher, David C.
    Herrera, Alex F.
    Davids, Matthew S.
    Shipp, Margaret A.
    Armand, Philippe
    Shouse, Geoffrey P.
    BLOOD, 2023, 142
  • [32] Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
    Tobinai, K
    Igarashi, T
    Itoh, K
    Kobayashi, Y
    Taniwaki, M
    Ogura, A
    Kinoshita, T
    Hotta, T
    Aikawa, K
    Tsushita, K
    Hiraoka, A
    Matsuno, Y
    Nakamura, S
    Morio, S
    Ohashi, Y
    ANNALS OF ONCOLOGY, 2004, 15 (05) : 821 - 830
  • [33] Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma
    Kedmi, Meirav
    Ribakovsy, Elena
    Benjamini, Ohad
    Schiby, Ginette
    Barshack, Iris
    Raskin, Stephen
    Eshet, Yael
    Mehr, Ramit
    Horowitz, Netanel
    Gurion, Ronit
    Goldschmidt, Neta
    Perry, Chava
    Levi, Itai
    Aviv, Ariel
    Herzog-Tzarfati, Katrin
    Nagler, Arnon
    Avigdor, Abraham
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (06)
  • [34] Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study
    Fukuhara, Noriko
    Suehiro, Youko
    Kato, Harumi
    Kusumoto, Shigeru
    Coronado, Cinthya
    Rappold, Erica
    Zhao, Wanying
    Li, Jia
    Gilmartin, Aidan
    Izutsu, Koji
    CANCER SCIENCE, 2022, 113 (05) : 1702 - 1711
  • [35] Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies
    Lyu, Jiaoyan
    Ma, Xiaopeng
    Huang, Ruiqi
    Zhao, Liyun
    Yu, Yiling
    Puig, Oscar
    Liu, Yang
    Hilger, James
    BLOOD, 2022, 140 : 3521 - 3522
  • [36] Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
    Chari, Ajai
    Cornell, Robert F.
    Gasparetto, Cristina
    Karanes, Chatchada
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Lunning, Matthew
    Usmani, Saad Z.
    Anderson, Larry D., Jr.
    Chhabra, Saurabh
    Girnius, Saulius
    Shustik, Chaim
    Stuart, Robert
    Lee, Yihua
    Salman, Zeena
    Liu, Emily
    Valent, Jason
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (03) : 353 - 362
  • [37] Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies
    Shadman, Mazyar
    Flinn, Ian W.
    Levy, Moshe Y.
    Porter, Ryan
    Burke, John M.
    Cultrera, Jennifer L.
    Misleh, Jamal
    Zafar, Syed F.
    Freeman, Benjamin
    Rao, Subramanya S.
    Yimer, Habte
    Chaudhry, Arvind
    Gandhi, Mitul D.
    Guthrie, Troy H.
    Kingsley, Edwin
    Tumula, Praveen K.
    Manda, Sudhir
    Chen, Dih-Yih
    Cohen, Aileen
    By, Kunthel
    Xu, Linlin
    Liu, Ye
    Sharman, Jeff P.
    BLOOD, 2021, 138
  • [38] Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
    Stephens, Deborah M.
    Huang, Ying
    Ruppert, Amy S.
    Walker, Janek S.
    Cempre, Casey B.
    Fu, Qiang
    Baker, Sharyn
    Hu, Boyu
    Shah, Harsh
    Vadeboncoeur, Renee
    Rogers, Kerry A.
    Bhat, Seema
    Jaglowski, Samantha M.
    Lockman, Hank
    Lapalombella, Rosa
    Byrd, John C.
    Woyach, Jennifer A.
    CLINICAL CANCER RESEARCH, 2022, 28 (15) : 3242 - 3247
  • [39] Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
    Stephens, Deborah M.
    Huang, Ying
    Agyeman, Akwasi
    Ruppert, Amy S.
    Hu, Boyu
    Turner, Natalie
    Vadeboncoeur, Renee
    Rogers, Kerry A.
    Bhat, Seema A.
    William, Basem M.
    Jaglowski, Samantha
    Lockman, Hank
    Glenn, Martha
    Lapalombella, Rosa
    Byrd, John C.
    Woyach, Jennifer
    BLOOD, 2019, 134
  • [40] A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Yoshiaki Ogawa
    Michinori Ogura
    Tatsuya Suzuki
    Kiyoshi Ando
    Toshiki Uchida
    Yukari Shirasugi
    Kensei Tobinai
    Je Hwan Lee
    Masazumi Kase
    Koichi Katsura
    Tomomitsu Hotta
    International Journal of Hematology, 2013, 98 : 164 - 170
12345